Structure Elucidation, Total Synthesis, Antibacterial In Vivo Efficacy and Biosynthesis Proposal of Myxobacterial Corramycin**
作者:Cédric Couturier、Sebastian Groß、Alexander von Tesmar、Judith Hoffmann、Selina Deckarm、Anouchka Fievet、Nelly Dubarry、Thomas Taillier、Christoph Pöverlein、Heike Stump、Michael Kurz、Luigi Toti、Sabine Haag Richter、Dietmar Schummer、Philippe Sizun、Michael Hoffmann、Ram Prasad Awal、Nestor Zaburannyi、Kirsten Harmrolfs、Joachim Wink、Emilie Lessoud、Thierry Vermat、Veronique Cazals、Sandra Silve、Armin Bauer、Michael Mourez、Laurent Fraisse、Corinne Leroi‐Geissler、Astrid Rey、Stéphanie Versluys、Eric Bacqué、Rolf Müller、Stephane Renard
DOI:10.1002/anie.202210747
日期:2022.12.19
natural product produced by the myxobacterium Corallococcus coralloides. The structure, extraordinary total synthesis and biosynthesis of the antibiotic is described for the first time. Its promise as an in vivo septicemia model, the absence of cross-resistance with commonly used antibiotic classes, and the lack of cytotoxicity make Corramycin a potential new drug in the fight against multidrug-resistant
Corramycin 是由珊瑚状珊瑚粘杆菌产生的新型天然产物。首次描述了该抗生素的结构、非凡的全合成和生物合成。它作为体内败血症模型的前景、与常用抗生素类别不存在交叉耐药性以及缺乏细胞毒性,使得 Corramycin 成为对抗多重耐药病原体的潜在新药。